Molecule to Market: Inside the outsourcing space

Beschikbare afleveringen

5 van 199

Charles River's lifelong CDMO leader
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kerstin Dolph, Senior Vice President of Manufacturing at Charles River Laboratories. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kerstin, covering: The value of having managers and mentors guide you and champion your success Navigating transitions from finance to operations and research to biologics manufacturing while becoming a senior leader at CRL Tackling the task of integrating testing and manufacturing at CRL globally to cut timelines for clients The importance of staying close and connected to the patient so you never lose sight of the impact of the work done in this space Stabilizing signs in the biotech market and pivoting to the market's needs in creative ways Kerstin joined Charles River 2001 in a Finance role for the Company’s Research Models and Services (RMS) business in Germany. She transitioned to the U.S. RMS business in 2009 and was promoted to Senior Finance Director of Global RMS in 2015. In 2017, Ms Dolph was promoted to Corporate Vice President of North American RMS, responsible for leading the Company’s North American RMS business. This included managing several consolidation and efficiency initiatives and global RMS technology enhancements. In 2019, Ms Dolph assumed the role of Corporate Vice President of Global Biologics. Subsequently, she assumed responsibility for the Company’s CDMO business and was promoted to senior vice president of biologics solutions in October 2021. Ms. Dolph is currently the Senior Vice President of Manufacturing. She is responsible for driving each business's strategic direction and future growth within the Company’s Manufacturing Solutions segment, including Biologics Testing Solutions, CDMO, and Microbial Solutions. Ms. Dolph holds a bachelor’s degree from the International Accountancy & Business School in Wuerzburg, Germany and was recognised by the Bavarian Government for outstanding performance. This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
--------
52:25
The pharma ingredients disruptor
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jack Stine, Chief Executive Officer at Savendor. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jack, covering: What he learned about supplier relationship management from exposure to 70 supply chain sourcing teams in 3M The shift to sourcing APIs and excipients for generics and med devices under FDA regulations How he always wanted to start a business, take the plunge, and fall in love with being a founder The actual trend of secondary sourcing... as opposed to immediate switching And what is Minnesota nice?! Since founding Savendor in 2023, Jack Stine has pioneered a new model for pharma sourcing teams to move faster, cut out intermediaries, added clients from 4 continents, and built an industry-leading portfolio of 331 pharmaceutical ingredient manufacturers. Savendor has been accepted into AstraZeneca’s Diverse and Small Business Mentorship Program and BetaMN’s startup accelerator. Jack has presented Savendor at both CPHI Philadelphia and CPHI Milan. Jack has worked in sourcing for over a decade. His career has brought him to APIs, excipients, industrial products, services, food, and medical device components. He has shared his knowledge by leading the Negotiations Training Team at Boston Scientific and speaking to undergraduates at the University of Minnesota’s Carlson School of Management. Jack has a Supply Chain Management Degree from the University of Minnesota and an MBA from IE Business School. Beyond sourcing and supply chain, Jack volunteers his time at the Ukrainian American Community Center as he is passionate about supporting people affected by the war in Ukraine. This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
--------
51:23
Baking success to IQVIA exit
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tessa Pugh, ex-CEO & Co-Founder at PharmaReview. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tessa, covering: How Tessa's bullish attitude led to her becoming a co-founder at PharmaReview Being the 'less educated person in the office', and using that to drive the growth of the business Opting not to leave after the sale of the business, and becoming the CEO Being the star player within a PE portfolio, leading to a quick exit to IQVIA Life lessons on having your cake...and eating it! Tessa Pugh is the former CEO & Co-founder PharmaReview, a Mum and an athlete. She spent 13 years working with Pharma companies and their agencies; she Co-Founded PharmaReview in 2011. Tessa was responsible for ensuring excellent client service, business development for both new and existing clients. She is a Pharma copy review process expert and became an expert in Veeva Vault functionality. Prior to this, she established a luxury direct-to-consumer cupcake company and worked in client service at some of the world’s leading advertising agencies including Saatchi & Saatchi and DRAFT. She is a very proud Mum to two incredible young women. Tessa has completed several marathons; has competed in triathlons and has won an age group national title in track cycling. She is currently following a life-long dream and training to be a ski instructor. This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
--------
55:28
The biotech-MedTech CEO tackling obesity
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr Camilla Easter, CEO at Oxford Medical Products. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Camilla, covering: Training long and hard as a Veterinary Surgeon surgeon... and then deciding to pivot into biotech Falling in love with the freedom and excitement of a start-up biotech while learning the importance of problem-solving and storytelling OMP's swelling hydrogel pill that reduces the space in your stomach and surpasses your appetite Developing a complementary product to GLP-1s to help tackle the 2billion+ global obesity challenge in a preventative, cheap, safe manner How OMPs unique, patented manufacturing process led it to in-house production and not outsourcing Lifting the lid on a recent selection process of choosing a global CRO partner to support upcoming clinical trials Camilla has over ten years of biotech start-up experience as CEO and COO, working exclusively on hydrogel-based therapeutics. Initially a veterinary surgeon, she has run veterinary clinical trials and launched the veterinary arm of a biotech company. Following this, she moved into the human biotech sector, where she has been involved in all aspects of start-ups, including, R&D, manufacturing scale-up, fundraising, regulatory, quality, pre-clinical and clinical trials for medical devices. Camilla joined the OMP team in 2019, initially to evaluate OMP technology. This led to the establishment of a team and the raising of the first round of external investment in 2020. OMP has developed Sirona, which, taken as a pill, rapidly expands in the stomach to create a sustained feeling of appetite suppression. Sirona remains in the stomach 24/7 for several days before breaking down and passing naturally. Since 2020, they have completed preclinical testing and phase 1 clinical trials. Sirona is now in phase 2a for obesity at three NHS sites, with results expected in Q4 2024. This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
--------
52:00
Delhi boy, done good
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Akshay Peer, co-founder and Senior Vice President of Products at TrakCel. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Akshay, covering: How the development of a patent led him into the CGT space—years before it was a market The founding story of TrakCel and getting GSK as an anchor client to support early iterations of its custom solution Fresh-in, frozen-out... just one of the variations of biospecimens to product in the crazy complex CGT supply chain Standardizing, streamlining, and harmonizing will become the de facto software choice for the avalanche of CGTs predicted to be approved by 2030 The decision to seek strategic investors (instead of financial investors) and the advantages it has brought to TrakCel Akshay is a co-founder and currently serves as the Senior Vice President of Product at TrakCel. Before this, he worked as the Business Development Lead for TrakCel for 8 years, from 2012 to 2018. He then took a break and worked as the CGT lead for Bluecrux. After a two-year hiatus, Akshay rejoined TrakCel’s team in September 2023 as the new head of product. He is an expert in software solutions to address the challenges of scaling cell and gene therapy products. Akshay has worked with companies developing autologous, allogeneic, CRISPR Cas-9, and other technology-based products. This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
--------
56:54

Meer Wetenschap podcasts

Trending Wetenschap -podcasts

Over Molecule to Market: Inside the outsourcing space

Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines. Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.

Podcast website

Luister naar Molecule to Market: Inside the outsourcing space, College van Kelder & Teulings en vele andere podcasts van over de hele wereld met de radio.net-app

Ontvang de gratis radio.net app

Zenders en podcasts om te bookmarken
Streamen via Wi-Fi of Bluetooth
Ondersteunt Carplay & Android Auto
Veel andere app-functies

App openen

Ontvang de gratis radio.net app

Zenders en podcasts om te bookmarken
Streamen via Wi-Fi of Bluetooth
Ondersteunt Carplay & Android Auto
Veel andere app-functies

Molecule to Market: Inside the outsourcing space

Scan de code,
download de app,
luisteren.

Molecule to Market: Inside the outsourcing space: Podcasts in familie

Modern Minorities
Maatschappij & cultuur, Persoonlijke dagboeken